Xenon Pharmaceuticals Inc.

XENE Healthcare Biotechnology

Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

33.55 0.78 −2.27%
Market cap
$3.3B
P/E
0.0×
Fwd P/E
−10.7×
Dividend yield
—
F-score
n/a
Altman Z
37.76
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
12.08 13.17 27.53 20.71
Current Ratio
12.52 13.42 27.79 21.02
Net Debt/EBITDA
4.83 5.03 9.80 7.59
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.79 0.77 0.87 0.86
Capex/Depreciation
(0.44) (0.52) (0.23) (0.49)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.91) (1.03) (1.02) (0.96)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.91) (1.03) (1.02) (0.96)
Cash per Share
5.83 6.93 12.53 9.34
Shareholders Equity per Share
7.06 7.34 15.32 12.47
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
7.06 7.34 15.32 12.47
Free Cash Flow
(72.03) (81.80) (89.03) (95.66)
Working Capital
441.80 518.86 1,066.82 900.86
Capital Expenditures
(0.28) (0.32) (0.13) (0.27)
Net Current Asset Value
431.81 509.25 1,057.64 892.49
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Receivables
0.88 1.42 4.91 1.36
Average Payables
32.57 37.24 34.45 37.63
Average Assets
721.87 715.65 1,065.05 985.03
Average Common Equity
678.66 668.33 1,020.89 938.19

Fold the line items

Columns are period end dates